PDIK1L

PDIK1L is a nuclear serine/threonine kinase that functions in a phosphatase-kinase signaling axis supporting cancer cell proliferation (PMID:35021089). It forms a physical complex with the nuclear phosphatase SCP4, serving as both a binding partner and a substrate: SCP4 activates PDIK1L by catalytically removing inhibitory phosphorylation and by promoting PDIK1L protein stability (PMID:35021089). Acting catalytically and redundantly with its paralog STK35 in the same pathway, PDIK1L sustains acute myeloid leukemia proliferation and supports amino acid biosynthesis and transport (PMID:35021089). In prostate cancer cells, PDIK1L promotes proliferation and confers resistance to PARP inhibitors, linking its activity to DNA repair and metabolic adaptation pathways (PMID:41262299). Beyond these findings, the direct kinase substrates of PDIK1L and the molecular basis of its nuclear localization have not been characterized in the available corpus.

1. 2003 Low

   Initial cloning established PDIK1L as a kinase-domain protein and predicted nuclear localization, defining it as a candidate signaling enzyme before any function was known.

   Evidence cDNA cloning from human foetal brain library with bioinformatics and subcellular localization inference

   PMID:14631099

   Open questions at the time

   • Nuclear localization and PDZ/LIM-protein interaction were predicted computationally, not experimentally validated
   • No catalytic activity or substrate demonstrated
   • No cellular function assigned
2. 2009 Low

   Comparative genomics placed PDIK1L within the vertebrate-conserved NKF4 kinase family alongside STK35, framing the paralog relationship later shown to be functionally redundant.

   Evidence Comparative genomics, synteny and gene-structure analysis, homology searches

   PMID:19756140

   Open questions at the time

   • Family assignment is purely computational
   • No functional experiments on PDIK1L itself
   • Redundancy with STK35 not yet tested
3. 2022 High

   Reciprocal complex isolation and genetic dissection answered how PDIK1L is regulated and where it acts, establishing it as an SCP4-activated kinase operating redundantly with STK35 to sustain leukemia proliferation and amino acid metabolism.

   Evidence AP-MS of affinity-purified complexes, CRISPR exon scanning, gene complementation, and domain-focused CRISPR screening in AML cells

   PMID:35021089

   Open questions at the time

   • Direct phosphorylation substrates of PDIK1L not identified
   • The specific inhibitory phosphosite(s) removed by SCP4 not mapped
   • Mechanistic link from kinase activity to amino acid biosynthesis/transport not resolved
4. 2025 Medium

   Loss- and gain-of-function in prostate cancer extended PDIK1L's pro-proliferative role to a new tumor context and tied its activity to PARP-inhibitor sensitivity and DNA repair/metabolic adaptation.

   Evidence Knockdown/overexpression in prostate cancer cell lines with proliferation and drug-sensitivity assays plus multi-omics pathway inference

   PMID:41262299

   Open questions at the time

   • Pathway placement inferred from multi-omics without direct biochemical validation
   • No demonstration that SCP4/STK35 axis operates in prostate cancer
   • Molecular mechanism connecting PDIK1L to DNA repair not established

• The direct catalytic substrates of PDIK1L and how its kinase activity mechanistically drives amino acid metabolism and DNA repair remain unresolved.
• No phosphorylation substrate identified
• No structural model of the PDIK1L-SCP4 complex
• Mechanism of nuclear recruitment unknown